

We claim:

1. A nucleic acid encoding NFIF-14b polypeptide comprising an amino acid sequence as shown in Figure 1 (SEQ ID NO: 1).
2. A nucleic acid encoding NFIF-7a polypeptide comprising an amino acid sequence as shown in Figure 2 (SEQ ID NO: 2).
3. The nucleic acid of Claim 1 wherein said DNA is a cDNA.
4. The nucleic acid of Claim 2 wherein said DNA is a cDNA.
5. An isolated and purified NFIF-14b polypeptide which induces NFκB and comprising an amino acid sequence as shown in Figure 1 (SEQ ID NO: 1).
6. An isolated and purified NFIF-7a polypeptide which induces NFκB and comprising an amino acid sequence as shown in Figure 2 (SEQ ID NO: 2).
7. A method of increasing expression of NFκB in a patient comprising introducing into the body of said patient a composition that induces NFκB.
8. The method of Claim 7 wherein said composition comprises an expression vector comprising a nucleic acid encoding NFIF-14b polypeptide.
9. The vector of Claim 8 selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and naked DNA vectors.
10. The method of Claim 7 wherein said composition comprises an expression vector comprising a nucleic acid encoding NFIF-7a polypeptide.

11. The vector of Claim 10 selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and naked DNA vectors.

12. The method of Claim 7 wherein said composition comprises a NFIF-14b polypeptide and a pharmaceutically acceptable carrier.

13. The method of Claim 7 wherein said composition comprises a NFIF-7a polypeptide and a pharmaceutically acceptable carrier.

14. A composition for lowering the expression of the NFIF gene in a patient comprising an antisense nucleic acid.

15. A composition for lowering the activity of an NFIF polypeptide in a patient comprising a neutralizing antibody that binds to an NFIF polypeptide and lowers its activity.

16. A composition for lowering the expression of NFIF in a patient comprising a ribozyme that cuts RNA encoding an NFIF polypeptide.

17. A method for evaluating whether a test compound is effective in inhibiting the activity of NFIF-14b based on the expression of an NFκB-regulated reporter gene comprising:

(A) comparing the level of NFκB-regulated gene expression in a first sample comprising: (1) NFIF-14b; (2) said NFκB-regulated reporter gene; and (3) said test compound with the level of gene expression in a second sample comprising (4) NFIF-14b; and (5) said NFκB-regulated reporter gene; and

(B) determining whether the expression of said reporter gene is lower in said first sample relative to said second sample.

18. A method for evaluating whether a test compound is effective in inhibiting the activity of NFIF-7a based on expression of an NFκB-regulated reporter gene comprising:

(A) comparing the level of NFκB-regulated gene expression in a first sample comprising: (1) NFIF-7a; (2) said NFκB-regulated reporter gene; and (3) said test compound with the level of gene expression in a second sample comprising: (4) NFIF-7a; and (5) said NFκB-regulated reporter gene; and

(B) determining whether the expression of said reporter gene is lower in said first sample relative to said second sample.

19. A method for identifying whether a test compound can enhance the activity of NFIF-14b based on the expression of an NFκB-regulated reporter gene comprising:

(A) comparing the level of NFκB-regulated gene expression in a first sample comprising (1) NFIF-14b; (2) said NFκB-regulated reporter gene; and (3) said test compound with the level of gene expression in a second sample comprising: (4) NFIF-14b; and (5) said NFκB-regulated reporter gene; and

(B) determining whether the expression of said reporter gene is higher in said first sample relative to said second sample.

20. A method for identifying compounds which enhance the activity of NFIF-7a based on the expression of an NFκB-regulated reporter gene comprising:

(A) comparing the level of NFκB-regulated gene expression in a first sample comprising: (1) NFIF-7a; (2) said NFκB-regulated reporter gene; and (3) said test compound with the level of gene expression in a second sample comprising: (4) NFIF-7a; and (5) said NFκB-regulated reporter gene; and

(B) determining whether the expression of said reporter gene is higher in said first sample relative to said second sample.

21. A method of inhibiting expression of NFκB-dependent genes comprising administration to a patient of a composition that inhibits the activity of NFIF-14b.

22. A method of inhibiting expression of NFκB-dependent genes comprising administration to a patient of a composition that inhibits the activity of NFIF-7a.

23. A method of inhibiting inflammation comprising administration of a composition that inhibits the activity of NFIF-14b.

24. A method of inhibiting inflammation comprising administration of a composition that inhibits the activity of NFIF-7a.

25. Use of an isolated NFIF polypeptide comprising an amino acid sequence of Figure 1 (SEQ ID NO: 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

26. Use of a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of Figure 1 (SEQ ID NO: 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

27. Use of a recombinant vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of Figure 1 (SEQ ID NO: 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

28. Use of a defective recombinant viral vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of Figure 1 (SEQ ID NO: 1) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

29. Use of an isolated NFIF polypeptide comprising an amino acid sequence of Figure 2 (SEQ ID NO: 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

30. Use of a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of Figure 2 (SEQ ID NO: 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

31. Use of a recombinant vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of Figure 2 (SEQ ID NO: 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.

32. Use of a defective recombinant viral vector comprising a nucleic acid encoding an NFIF polypeptide comprising an amino acid sequence of Figure 2 (SEQ ID NO: 2) for the manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response.